Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Therapeutics Acquisition Corp Cl A (RACA)

Therapeutics Acquisition Corp Cl A (RACA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 144,261
  • Shares Outstanding, K 14,041
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 28.85
Trade RACA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.90 +3.78%
on 06/29/21
10.62 -3.25%
on 06/09/21
-0.05 (-0.44%)
since 05/28/21
3-Month
9.81 +4.73%
on 04/20/21
10.89 -5.67%
on 04/06/21
-0.18 (-1.68%)
since 03/30/21

Most Recent Stories

More News
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company

Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol “PNT”

RACA : 10.27 (+2.19%)
Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT

Therapeutics Acquisition Corp, d/b/a Research Alliance Corp. I, a Delaware corporation (“the Company”) (Nasdaq: RACA) announced today that its registration statement on Form S-4 (File Number 333-254600)...

RACA : 10.27 (+2.19%)
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC

POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed...

RACA : 10.27 (+2.19%)
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC

INDIANAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients,...

RACA : 10.27 (+2.19%)
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today that the U.S. Nuclear Regulatory...

RACA : 10.27 (+2.19%)
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today that the U.S. Nuclear Regulatory...

RACB : 10.11 (+0.45%)
RACA : 10.27 (+2.19%)
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I

POINT Biopharma has entered into a definitive merger agreement with Research Alliance Corp. I (Nasdaq: RACA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker symbol...

RACA : 10.27 (+2.19%)
Cerevance Appoints David Lubner to Board of Directors

Life sciences industry veteran brings more than 25 years of financial and operational experience

DYN : 23.69 (-5.14%)
RACA : 10.27 (+2.19%)
NITE : 25.41 (-0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Therapeutics Acquisition Corp. is a blank check company. It aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase and reorganization. Therapeutics Acquisition Corp. is based in Boston, United States.

See More

Key Turning Points

3rd Resistance Point 10.73
2nd Resistance Point 10.53
1st Resistance Point 10.40
Last Price 10.27
1st Support Level 10.07
2nd Support Level 9.87
3rd Support Level 9.74

See More

52-Week High 21.44
Fibonacci 61.8% 17.00
Fibonacci 50% 15.63
Fibonacci 38.2% 14.25
Last Price 10.27
52-Week Low 9.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar